Pressure associated with competition and reimbursement may erode GenMark's market share and product pricing, JP Morgan said.
The firm reported full year revenues of $54.4 million and fiscal Q4 revenues of $15.7 million, beating the consensus Wall Street estimates for both.
Science reports a new US defense bill would establish two groups aimed at combating foreign influence on research.
Nature Biotechnology discusses promising early results from two clinical trials of CRISPR-based therapy for β-thalassemia and sickle cell disease.
In Cell this week: analysis of tissue clones, metagenomic studies of ocean water samples, and more.
Researchers at Baylor College of Medicine and Columbia University found that almost all blood samples from pregnant women tested contained several trophoblasts.
In a proof-of-principle study, Ohio State University researchers compared the nanopore sequencing assay to short-read sequencing and capillary electrophoresis.
The genomics-focused fertility management company claims that 23andMe failed to meet its contractual obligations within a research collaboration.
The firm also said it is contemplating selling its therapeutics division, and appointed David Bench as its new CFO.
The firm has entered the market in Africa with a new collaboration in Ghana. It is also developing instrument-agnostic STI and liquid biopsy tests.
In a cartoon, Vox explores the lack of women among this year's winners of the Nobel Prize.